107 related articles for article (PubMed ID: 17003395)
1. Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
Balmaña J; Stockwell DH; Steyerberg EW; Stoffel EM; Deffenbaugh AM; Reid JE; Ward B; Scholl T; Hendrickson B; Tazelaar J; Burbidge LA; Syngal S
JAMA; 2006 Sep; 296(12):1469-78. PubMed ID: 17003395
[TBL] [Abstract][Full Text] [Related]
2. Rare single-nucleotide variants of MLH1 and MSH2 genes in patients with Lynch syndrome.
Mirabdolhosseini SM; Yaghoob Taleghani M; Rejali L; Sadeghi H; Fatemi N; Tavallaei M; Famil Meyari A; Saeidi N; Ketabi Moghadam P; Sadeghi A; Asadzadeh Aghdaei H; Zali MR; Nazemalhosseini Mojarad E
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1930. PubMed ID: 37919876
[TBL] [Abstract][Full Text] [Related]
3. Rapid development of colorectal neoplasia in patients with Lynch syndrome.
Edelstein DL; Axilbund J; Baxter M; Hylind LM; Romans K; Griffin CA; Cruz-Correa M; Giardiello FM
Clin Gastroenterol Hepatol; 2011 Apr; 9(4):340-3. PubMed ID: 21070872
[TBL] [Abstract][Full Text] [Related]
4. Uptake of genetic testing by the children of Lynch syndrome variant carriers across three generations.
Seppälä TT; Pylvänäinen K; Mecklin JP
Eur J Hum Genet; 2017 Nov; 25(11):1237-1245. PubMed ID: 28832568
[TBL] [Abstract][Full Text] [Related]
5. Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed.
Hicks S; Wheeler DA; Plon SE; Kimmel M
Hum Mutat; 2011 Jun; 32(6):661-8. PubMed ID: 21480434
[TBL] [Abstract][Full Text] [Related]
6. Influence of family history on penetrance of hereditary cancers in a population setting.
Jackson L; Weedon MN; Green HD; Mallabar-Rimmer B; Harrison JW; Wood AR; Ruth KS; Tyrrell J; Wright CF
EClinicalMedicine; 2023 Oct; 64():102159. PubMed ID: 37936660
[TBL] [Abstract][Full Text] [Related]
7. Beliefs about cancer and diet among those considering genetic testing for colon cancer.
Palmquist AE; Upton R; Lee S; Panter AT; Hadley DW; Koehly LM
J Nutr Educ Behav; 2011; 43(3):150-6. PubMed ID: 21296025
[TBL] [Abstract][Full Text] [Related]
8. Novel MSH2 Mutation in the First Report of a Vietnamese-American Kindred with Lynch Syndrome.
Eskander RN; Lynch HT; Brown SM; Wagman LD; Tewari KS
Gynecol Oncol Rep; 2015 Apr; 12():31-3. PubMed ID: 26076155
[TBL] [Abstract][Full Text] [Related]
9. Pathological Features of Colorectal Adenocarcinoma Patients Related to MLH1.
Bratei AA; Stefan-van Staden RI
Cell Mol Bioeng; 2024 Apr; 17(2):153-164. PubMed ID: 38737450
[TBL] [Abstract][Full Text] [Related]
10. Retraction Note: Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.
Basu M; Mukhopadhyay D; Chakraborty B; Ghosh S; Pal DK; Ghosh A; Panda CK
Mol Cell Biochem; 2024 May; ():. PubMed ID: 38696002
[No Abstract] [Full Text] [Related]
11. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.
Kastrinos F; Steyerberg EW; Mercado R; Balmaña J; Holter S; Gallinger S; Siegmund KD; Church JM; Jenkins MA; Lindor NM; Thibodeau SN; Burbidge LA; Wenstrup RJ; Syngal S
Gastroenterology; 2011 Jan; 140(1):73-81. PubMed ID: 20727894
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.
Kastrinos F; Steyerberg EW; Balmaña J; Mercado R; Gallinger S; Haile R; Casey G; Hopper JL; LeMarchand L; Lindor NM; Newcomb PA; Thibodeau SN; Syngal S;
Gut; 2013 Feb; 62(2):272-9. PubMed ID: 22345660
[TBL] [Abstract][Full Text] [Related]
13. Prediction of germline mutations and cancer risk in the Lynch syndrome.
Chen S; Wang W; Lee S; Nafa K; Lee J; Romans K; Watson P; Gruber SB; Euhus D; Kinzler KW; Jass J; Gallinger S; Lindor NM; Casey G; Ellis N; Giardiello FM; Offit K; Parmigiani G;
JAMA; 2006 Sep; 296(12):1479-87. PubMed ID: 17003396
[TBL] [Abstract][Full Text] [Related]
14. Development and evaluation of INT
Isidro RA; Chittenden A; Walker M; Schwartz A; Koeller DR; Hayes CP; Unal B; Manam MD; Buehler RM; Manning DK; Sholl LM; Redston MS; Yurgelun MB; Rana HQ; Garber JE; Ghazani AA
Front Oncol; 2023; 13():1284690. PubMed ID: 38344144
[TBL] [Abstract][Full Text] [Related]
15. PREDICTION OF HEREDITARY CANCERS USING NEURAL NETWORKS.
Guan BZ; Parmigiani G; Braun D; Trippa L
Ann Appl Stat; 2022 Mar; 16(1):495-520. PubMed ID: 37873507
[TBL] [Abstract][Full Text] [Related]
16. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer.
Lee NY; Hum M; Zihara S; Wang L; Myint MK; Lim DW; Toh CK; Skanderup A; Samol J; Tan MH; Ang P; Lee SC; Tan EH; Lai GGY; Tan DSW; Yap YS; Lee ASG
Hum Genomics; 2023 Jul; 17(1):66. PubMed ID: 37461096
[TBL] [Abstract][Full Text] [Related]
17. Updates in gynecologic care for individuals with lynch syndrome.
Underkofler KA; Ring KL
Front Oncol; 2023; 13():1127683. PubMed ID: 36937421
[TBL] [Abstract][Full Text] [Related]
18. A validation of models for prediction of pathogenic variants in mismatch repair genes.
Shyr C; Blackford AL; Huang T; Ke J; Ouardaoui N; Trippa L; Syngal S; Ukaegbu C; Uno H; Nafa K; Stadler ZK; Offit K; Amos CI; Lynch PM; Chen S; Giardiello FM; Buchanan DD; Hopper JL; Jenkins MA; Southey MC; Win AK; Figueiredo JC; Braun D; Parmigiani G
Genet Med; 2022 Oct; 24(10):2155-2166. PubMed ID: 35997715
[TBL] [Abstract][Full Text] [Related]
19. miRGTF-net: Integrative miRNA-gene-TF network analysis reveals key drivers of breast cancer recurrence.
Nersisyan S; Galatenko A; Galatenko V; Shkurnikov M; Tonevitsky A
PLoS One; 2021; 16(4):e0249424. PubMed ID: 33852600
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.
Leclerc J; Vermaut C; Buisine MP
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
